1.
Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal...
by Matyas, Gary R
Vaccine, 18 July 2011, Vol.29(32), pp.5137-5144
2.
Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21
by Beck, Zoltan
Vaccine, 13 October 2015, Vol.33(42), pp.5578-5587
3.
Adjuvants for vaccines to drugs of abuse and addiction
by Alving, Carl R
Vaccine, 22 September 2014, Vol.32(42), pp.5382-5389
4.
A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologicall...
by Sulima, Agnieszka
Journal of medicinal chemistry, 11 January 2018, Vol.61(1), pp.329-343
5.
Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness
by Phillips, Christopher J
Vaccine, 12 June 2009, Vol.27(29), pp.3921-3926
6.
Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs
by Matyas, Gary R
Vaccine, 10 June 2013, Vol.31(26), pp.2804-2810
7.
Highly effective generic adjuvant systems for orphan or poverty-related vaccines
by Rao, Mangala
Vaccine, 29 January 2011, Vol.29(5), pp.873-877
8.
Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants
by Seth, Labdhi
Vaccine, 04 October 2017, Vol.35(41), pp.5448-5454
9.
Designing the epitope flanking regions for optimal generation of CTL epitopes
by Steers, Nicholas J
Vaccine, 12 June 2014, Vol.32(28), pp.3509-3516
10.
Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
by Zollinger, Wendell D
Vaccine, 2012, Vol.30(4), pp.712-721
11.
Lipid A and liposomes containing lipid A as antigens and adjuvants
by Alving, Carl R
Vaccine, 2008, Vol.26(24), pp.3036-3045
12.
Antibodies to Lipids and Liposomes: Immunology and Safety
by Alving, Carl R
Journal of Liposome Research, 01 January 2006, Vol.16(3), pp.157-166
13.
Facial recognition of heroin vaccine opiates: Type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine
by Matyas, Gary R
Vaccine, 14 March 2014, Vol.32(13), pp.1473-1479
14.
Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013
by Genito, Christopher J
Vaccine, 05 July 2017, Vol.35(31), pp.3865-3874
15.
Design and selection of vaccine adjuvants: animal models and human trials
by Alving, Carl R
Vaccine, 2002, Vol.20, pp.S56-S64
16.
Oil-in-water liposomal emulsions: Characterization and potential use in vaccine delivery
by Muderhwa, Jean M
Journal of Pharmaceutical Sciences, December 1999, Vol.88(12), pp.1332-1339
17.
Modulation of immunoproteasome subunits by liposomal lipid A
by Steers, Nicholas J
Vaccine, 2008, Vol.26(23), pp.2849-2859
18.
Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells
by Rao, Mangala
Advanced Drug Delivery Reviews, 2000, Vol.41(2), pp.171-188
19.
Transcutaneous immunization: T cell responses and boosting of existing immunity
by Hammond, Scott A
Vaccine, 2001, Vol.19(17), pp.2701-2707
20.
Advances in vaccine delivery: transcutaneous immunisation
by Glenn, Gregory M
Expert Opinion on Investigational Drugs, 01 June 1999, Vol.8(6), pp.797-805
Filter electronic articles 27 Hits
Remove Filters
